VIA
IBB icon

Vantage Investment Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Vantage Investment Advisors’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-3
Closed – – 785
2017
Q1 		$0 Hold
3
– – ﹤0.01% 782
2016
Q4 		$0 Sell
3
-150
-98% -$13.7K ﹤0.01% 821
2016
Q3 		$15K Sell
153
-213
-58% -$20.3K 0.01% 431
2016
Q2 		$27K Buy
366
+90
+33% +$8.07K 0.01% 358
2016
Q1 		$24K Buy
276
+36
+15% +$3.22K 0.01% 375
2015
Q4 		$27K Hold
240
– – 0.01% 330
2015
Q3 		$24K Buy
240
+90
+60% +$10.8K 0.01% 333
2015
Q2 		$18K Sell
150
-150
-50% -$18K 0.01% 393
2015
Q1 		$34K Buy
300
+150
+100% +$16.5K 0.01% 403
2014
Q4 		$15K Hold
150
– – 0.01% 436
2014
Q3 		$14K Hold
150
– – 0.01% 427
2014
Q2 		$13K Hold
150
– – 0.01% 437
2014
Q1 		$12K Hold
150
– – 0.01% 409
2013
Q4 		$11K Buy
+150
New +$10.6K 0.01% 396

Other funds holding IBB

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
CM
Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Vantage Investment Advisors's IBB Position: Q2 2017 in Review

Vantage Investment Advisors sold out of iShares Biotechnology ETF (IBB) in Q2 2017, closing a stake of 3 shares.

Vantage Investment Advisors first reported a position in IBB in Q4 2013 and held it in 14 quarters. The position peaked at $34K in Q1 2015. 562 funds tracked by Wall St. Rank hold IBB as of Q2 2017.

  • Vantage Investment Advisors reported no remaining iShares Biotechnology ETF position as of Q2 2017 after selling out during the quarter.
  • Vantage Investment Advisors sold 3 iShares Biotechnology ETF shares in Q2 2017.
  • Vantage Investment Advisors first reported a position in iShares Biotechnology ETF in Q4 2013 and held it in 14 quarters.
  • Vantage Investment Advisors's iShares Biotechnology ETF position peaked at $34K in Q1 2015.
  • 562 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2017.

Based on Vantage Investment Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.